Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation